We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Controlling the Half-Life of Pathological IgG and Therapeutic Antibodies
Application Note

Controlling the Half-Life of Pathological IgG and Therapeutic Antibodies

Controlling the Half-Life of Pathological IgG and Therapeutic Antibodies
Application Note

Controlling the Half-Life of Pathological IgG and Therapeutic Antibodies

Various autoimmune diseases (e.g., myasthenia gravis) are mediated by IgG autoantibodies. To address this mechanism of autoimmunity, researchers are exploring the therapeutic use of FcRn inhibitors in an effort to decrease the pathogenesis of IgG and develop new therapies.

In addition, there has been work focused on the FcRn pathway as a means to prolong the half-life of therapeutic antibodies.

Download this app note to learn more about:

  • FcRn antagonists currently being developed to treat autoimmune diseases
  • How antibody binding to FcRn can be enhanced using biomolecular engineering approaches
  • Various high-quality FcRn proteins and how they are supporting the development of antibody drugs
Advertisement